FDA Pre-Approval Inspection for Pre-Filled Syringe Product Completed with No Form 483 Observations
January 21, 2020, Bedford, NH – LSNE Contract Manufacturing (LSNE), a privately held contract development and manufacturing organization, is pleased to announce a successful Pre-Approval Inspection (PAI) performed by the US Food and Drug Administration (FDA) at its aseptic fill finish facility in León, Spain. The inspection took place this month and LSNE was found to be compliant with no Form 483 observations issued. LSNE-León is now positioned to support commercial manufacturing of a sterile injectable product in a pre-filled syringe presentation.
“This inspection was a critical milestone for LSNE and its newest site within LSNE’s global network. This marks the second successful FDA inspection at LSNE-León and demonstrates the site’s alignment and commitment to LSNE’s core values of quality and compliance” said Tom McGrath, VP of Quality & Regulatory.
Shawn Cain, Chief Operating Officer said, “We are proud of our León team and to add another successful inspection to our long track record of compliance. As we continue to grow, quality is always at the forefront of our business so that we can best serve our clients and their patients. It is only through the hard work and dedication of our team that we have been able to achieve and maintain this high level of integrity, quality, and consistency.”